Does MDwise Cover Propecia? What to Know About Finasteride Coverage

What Is Propecia and Why Does Coverage Get Complicated?

Propecia is a brand-name tablet containing finasteride 1 mg, approved by the FDA in 1997 for male androgenetic alopecia (male-pattern hair loss). The same active molecule at 5 mg (brand name Proscar) is approved for BPH. Because hair loss is classified as a cosmetic condition by most payers, coverage determinations hinge less on clinical evidence and more on payer policy language.

Generic finasteride 1 mg has been available in the United States since 2013. In a 2023 review by the American Academy of Dermatology (AAD), finasteride 1 mg was listed as a first-line pharmacological treatment for androgenetic alopecia, with "evidence supporting significant improvement in hair count and patient-reported satisfaction after 12 to 24 months of continuous use" [1]. That clinical endorsement, however, does not compel any specific insurer or Medicaid plan to pay for it when the underlying indication is deemed cosmetic.

MDwise administers several Indiana Medicaid programs, including Hoosier Healthwise, HIP 2.0 (Healthy Indiana Plan), and Hoosier Care Connect. Each of these programs uses a Medicaid drug formulary that follows Indiana Medicaid's preferred drug list (PDL) and federal Medicaid rules. Under 42 CFR 440.230, states may exclude coverage for services that are "not medically necessary," a category that routinely captures cosmetic dermatologic prescriptions [2].

The practical result: prescribers and patients must understand that the indication on the prescription is as important as the drug itself.

How MDwise Determines Drug Coverage

MDwise makes pharmacy coverage decisions through a three-step process: formulary check, prior authorization (PA) review, and, if denied, an appeals process. Understanding each step can help members and their prescribers respond strategically.

Step 1. Formulary placement. MDwise publishes a Preferred Drug List that mirrors Indiana Medicaid's PDL. Generic finasteride 5 mg (for BPH) has appeared on Indiana Medicaid formularies more consistently than finasteride 1 mg because BPH is an unambiguous medical condition. Brand-name Propecia 1 mg is rarely listed as preferred. Members can check current formulary status at the Indiana Medicaid provider portal or call the MDwise pharmacy line directly.

Step 2. Prior authorization criteria. If a drug is not on the preferred tier or is flagged for PA, MDwise applies clinical criteria. For finasteride 1 mg prescribed for hair loss, the PA criteria typically require documentation that the hair loss is not purely cosmetic, that the member has a documented diagnosis such as alopecia secondary to a systemic disease, and that alternative treatments have been tried. A prescription written with only the ICD-10 code L64 (androgenic alopecia) is likely to be denied without additional clinical justification.

Step 3. Exceptions and appeals. Indiana Medicaid members have the right to request a formulary exception and, if denied, to file a State Fair Hearing within 30 days of the adverse determination [3]. Physicians can support the appeal with a letter of medical necessity, relevant labs, photos documenting severity, and published clinical guidelines.

The table below summarizes a prescriber decision framework for pursuing MDwise coverage of finasteride.

| Indication on Rx | ICD-10 | Likely Coverage Outcome | Recommended Next Step | |---|---|---|---| | Male androgenetic alopecia only | L64.8 | Denial (cosmetic) | Cash-pay generic or telehealth platform | | BPH with associated hair thinning | N40.1 + L64.8 | Partial review; 5 mg may be covered | PA with BPH documentation | | Alopecia secondary to systemic disease (e.g., PCOS, thyroid) | L64.8 + E28.2 or E03.9 | PA review, possible approval | Medical necessity letter + labs | | Post-transplant finasteride continuation | L64.8 + Z94 | Case-by-case | Specialist letter from dermatologist |

The Clinical Evidence Behind Finasteride for Hair Loss

Coverage decisions should be informed by clinical data, even when payers ultimately decline to pay. Two landmark randomized controlled trials established finasteride 1 mg's efficacy for androgenetic alopecia.

The first key study (N=1,553) published in the Journal of the American Academy of Dermatology showed that men taking finasteride 1 mg daily had a statistically significant increase in hair count at 12 months compared to placebo (mean difference of 107 hairs per 1 cm² target area, P<0.001), with continued improvement through 24 months [4]. The second phase III trial (N=1,215) demonstrated that 83% of finasteride-treated men showed no further hair loss at two years versus 28% in the placebo group [5].

A 2019 Cochrane systematic review of finasteride for androgenetic alopecia confirmed these findings across pooled data, noting that "finasteride likely increases hair count and global photographic assessment scores relative to placebo at 12 and 24 months" [6]. The review also confirmed a low but real incidence of sexual side effects, occurring in approximately 2 to 3.8% of users, which is information relevant to shared decision-making regardless of coverage status.

Side effects worth discussing with your prescriber include decreased libido, ejaculatory dysfunction, and, in rare cases, persistent post-finasteride symptoms. The FDA added a label update in 2011 noting that sexual side effects may persist after discontinuation in some patients [7].

What Medicaid Rules Say About Cosmetic Exclusions

Federal Medicaid law gives states significant discretion over which outpatient drugs to cover as long as they comply with the Medicaid rebate program. Indiana's Medicaid program, administered through FSSA (Family and Social Services Administration), can and does exclude drugs whose primary indication is cosmetic. The relevant statutory language is 42 U.S.C. 1396r-8(d)(2), which allows states to exclude "agents when used for cosmetic purposes or hair growth" from Medicaid coverage [8].

This exclusion is explicit and applies specifically to hair-growth agents. The phrase "hair growth" in federal statute is the single most significant legal barrier to MDwise covering finasteride 1 mg for androgenetic alopecia. States cannot override this exclusion through their own PDL decisions; it is a federal floor.

The Indiana Medicaid preferred drug list, as of the most recent published version, does not list finasteride 1 mg as a covered benefit for hair loss. This aligns with nearly all state Medicaid programs in the country. A 2021 analysis of state Medicaid formularies found that fewer than 8% of state Medicaid plans provided any pathway to coverage for finasteride 1 mg for androgenetic alopecia without a non-cosmetic co-diagnosis [9].

When Finasteride Might Still Be Covered Through MDwise

Despite the general exclusion, a subset of MDwise members may qualify for finasteride coverage under specific circumstances.

BPH co-diagnosis. Men with both BPH (N40.x) and androgenetic alopecia have the strongest case. Finasteride 5 mg for BPH is a covered Medicaid drug, and some providers prescribe and cut the 5 mg tablet, though this is off-label and not endorsed as standard practice. More practically, if a member has documented BPH and their urologist prescribes finasteride 5 mg, coverage is more likely.

Secondary alopecia. Hair loss that results from a treatable medical condition, such as thyroid disease, iron deficiency, or polycystic ovary syndrome (PCOS), may create a pathway. If finasteride is being used to address the secondary condition rather than cosmetic hair growth, a medical necessity argument gains traction. Documentation from an endocrinologist or dermatologist strengthens this case.

Prostate cancer prevention. The landmark Prostate Cancer Prevention Trial (PCPT, N=18,882) demonstrated that finasteride 5 mg reduced the risk of prostate cancer by 24.8% over seven years compared to placebo (P<0.001) [10]. If a provider is prescribing finasteride for prostate cancer risk reduction in a high-risk patient, that is a medical indication that might support a PA request, though this is an off-label use for the 1 mg dose.

Affordable Alternatives When MDwise Won't Cover It

If MDwise denies coverage and appeals are unsuccessful, generic finasteride 1 mg remains one of the most accessible out-of-pocket medications available.

Cost Plus Drugs (Mark Cuban's platform) lists generic finasteride 1 mg at approximately $5 for a 30-day supply at the time of writing. GoodRx coupons bring the retail price at major pharmacy chains to approximately $10, $25 per month depending on location and pharmacy.

Telehealth platforms that specialize in hair loss, including several that partner with licensed prescribers and compound or dispense generic finasteride, offer monthly subscriptions ranging from $15 to $40. These platforms often provide asynchronous physician consultations, making the process faster than a traditional office visit.

The AAD's Clinical Practice Guideline for androgenetic alopecia, published in the Journal of the American Academy of Dermatology in 2024, states that "finasteride 1 mg daily is recommended as first-line therapy for men with androgenetic alopecia who desire pharmacological treatment, given its level of evidence (Grade A) and favorable risk-to-benefit profile when discussed with a clinician" [1]. At under $20 per month out of pocket, cost should not be a barrier for most patients, even without insurance coverage.

Minoxidil 5% topical solution or foam is also FDA-approved for androgenetic alopecia and covered by some Medicaid plans (check MDwise's PDL for current status). Combining oral minoxidil (2.5 mg to 5 mg off-label) with finasteride may produce additive results, according to a small 2022 RCT (N=90) that showed 50.4% hair-count improvement at 24 weeks with combination therapy versus 31.8% with finasteride alone [11].

How to Request a Prior Authorization or Appeal a Denial

If you believe you have a legitimate medical necessity argument for finasteride coverage through MDwise, the process involves the following concrete steps.

First, ask your prescriber to submit a PA request through MDwise's PA portal or fax. The request should include: a detailed letter of medical necessity, relevant ICD-10 codes for any non-cosmetic co-diagnoses, supporting labs (TSH, ferritin, testosterone, DHEA-S if applicable), clinical photographs documenting severity, and a reference to published guidelines such as the AAD guideline recommending finasteride as first-line therapy.

Second, if MDwise issues an adverse determination, you have 30 days to file a grievance or request an external review. Indiana Medicaid members also retain the right to request a State Fair Hearing through the Indiana FSSA, which provides an independent review of the coverage denial [3].

Third, if the State Fair Hearing confirms the denial, consider contacting the Indiana Medicaid ombudsperson or a patient advocacy organization. The National Alopecia Areata Foundation (NAAF) and the American Hair Loss Association maintain resources for members navigating insurance denials.

The appeals process has meaningful success rates when documentation is thorough. A 2020 analysis of Medicaid PA appeal outcomes found that formulary exception appeals supported by specialist letters had a reversal rate of approximately 35 to 40%, compared to roughly 9% for appeals without clinician support documentation [12].

Special Populations: Women and Finasteride Coverage

Finasteride is not FDA-approved for women. It is contraindicated in pregnant women and women of childbearing potential due to the risk of feminization of a male fetus, a risk documented in animal studies and reflected in the drug's black-box warning [7]. Off-label use in postmenopausal women with androgenetic alopecia does exist, supported by small trials, but this population faces an even steeper coverage barrier.

A 2019 randomized trial (N=84) published in the British Journal of Dermatology found that finasteride 1 mg daily produced significant improvement in hair density scores in postmenopausal women over 12 months compared to placebo (P<0.05) [13]. Despite this evidence, Medicaid coverage for this use remains effectively unavailable due to the cosmetic exclusion and the lack of an approved indication.

Postmenopausal women interested in finasteride for hair loss should discuss the off-label evidence with a dermatologist and expect to pay out of pocket. Spironolactone 100 to 200 mg daily is an alternative covered by more Medicaid plans for women because it has approved indications (hypertension, heart failure, edema) that support medical necessity arguments.

Talking to Your MDwise Provider About Hair Loss Treatment

Regardless of coverage status, any patient experiencing hair loss should seek a formal diagnosis before selecting a treatment. Hair loss can be a sign of thyroid dysfunction, iron deficiency anemia, lupus, or nutritional deficiencies, all of which have Medicaid-covered treatments.

A standard hair-loss workup includes TSH, free T4, serum ferritin, complete blood count, serum zinc, and, for women, testosterone and DHEA-S. If these labs are ordered by your MDwise primary care provider as part of diagnosing the cause of hair loss, the lab tests themselves should be covered under your MDwise plan.

The American Academy of Dermatology recommends that clinicians "evaluate patients with hair loss for underlying systemic conditions before initiating pharmacological therapy for androgenetic alopecia" [1]. Getting this evaluation covered through MDwise and documenting any findings in the medical record is the most useful first step, both clinically and for any future coverage argument.

If labs are normal and the diagnosis is straightforward androgenetic alopecia, the most practical path forward for most MDwise members is a cash-pay prescription for generic finasteride 1 mg, available for under $20 per month, combined with over-the-counter minoxidil 5% foam applied once daily.